Literature DB >> 16273796

Assessment of systemic lupus erythematosus.

G K W Lam1, M Petri.   

Abstract

Systemic lupus erythematosus (SLE) is the archetypal autoimmune disease given its complex clinical and molecular manifestations. Like the other rheumatic diseases, appropriate management is critically dependent upon the proper assessment of disease activity, organ damage, and quality of life. Here, we describe the components of the comprehensive assessment of SLE, including accurate physical and laboratory diagnosis, monitoring of disease activity, recording of accumulated organ morbidity, and integration of these with the patient's own perceptions of health status and quality of life. In doing so, we will review the most appropriate laboratory tests and indices currently used in standard clinical care and in clinical research.

Entities:  

Mesh:

Year:  2005        PMID: 16273796

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  48 in total

1.  Belimumab (benlysta): a breakthrough therapy for systemic lupus erythematosus.

Authors:  Raymond Lamore; Sapna Parmar; Khilna Patel; Olga Hilas
Journal:  P T       Date:  2012-04

2.  Critique and appraisal of a study on sex disparities in systemic lupus erythematosus.

Authors:  Jeannette M Olazagasti
Journal:  Rheumatol Int       Date:  2013-11-19       Impact factor: 2.631

3.  Detection of asymptomatic cranial neuropathies in patients with systemic lupus erythematosus and their relation to antiribosomal P antibody levels and disease activity.

Authors:  Wafaa Gaber; Yasser Ezzat; Neveen M El Fayoumy; Hanan Helmy; Abeer M Mohey
Journal:  Clin Rheumatol       Date:  2014-05-24       Impact factor: 2.980

4.  Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.

Authors:  Rachel S Klein; Pamela A Morganroth; Victoria P Werth
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 5.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

6.  Impact of the longitudinal quantitative assessment of juvenile systemic lupus erythematosus severity on the disease outcome.

Authors:  Maria Trachana; Polyxeni Pratsidou-Gertsi; Florence Kanakoudi-Tsakalidou; Vasiliki Tzimouli; Nikoleta Printza; Fotis Papachristou
Journal:  Clin Rheumatol       Date:  2020-07-07       Impact factor: 2.980

7.  Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus.

Authors:  M Pejchinovski; J Siwy; W Mullen; H Mischak; M A Petri; L C Burkly; R Wei
Journal:  Lupus       Date:  2017-05-05       Impact factor: 2.911

8.  Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare.

Authors:  Melissa E Munroe; Evan S Vista; Joel M Guthridge; Linda F Thompson; Joan T Merrill; Judith A James
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

9.  Targeting Notch signaling in autoimmune and lymphoproliferative disease.

Authors:  David T Teachey; Alix E Seif; Valerie I Brown; Marlo Bruno; Ralph M Bunte; Yueh J Chang; John K Choi; Jonathan D Fish; Junior Hall; Gregor S Reid; Theresa Ryan; Cecilia Sheen; Patrick Zweidler-McKay; Stephan A Grupp
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

10.  Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases.

Authors:  Hui Zheng; Yi Chen; Wen Ao; Yan Shen; Xiao-wei Chen; Min Dai; Xiao-dong Wang; Yu-cheng Yan; Cheng-de Yang
Journal:  Arthritis Res Ther       Date:  2009-06-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.